Physician profile
Melissa Bogle
NPI 1972097103
$6,070.15
in general payments reported to CMS, 2019-2025
53 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,358 · 2022: $1,402 · 2023: $380 · 2024: $510 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.94 |
| Education | $483.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $577.39 | 2021-2025 | |
| Seagen INC. | $370.23 | 2021-2025 | |
| Pfizer INC. | $364.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $359.82 | 2021-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals LP | $357.49 | 2021-2023 | Imfinzi |
| Incyte Corporation | $346.14 | 2021-2025 | Jakafi |
| Janssen Biotech, INC. | $339.73 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $325.35 | 2024-2025 | |
| Amgen INC. | $314.24 | 2021-2023 | Kyprolis, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $232.01 | 2021-2025 | Opdivo |
| Karyopharm Therapeutics INC. | $155.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $148.33 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $146.30 | 2021-2023 | Imbruvica |
| Celgene Corporation | $145.02 | 2021-2025 | Breyanzi |
| Genzyme Corporation | $141.54 | 2021-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.